Literature DB >> 9218456

Syk is required for BCR-mediated activation of p90Rsk, but not p70S6k, via a mitogen-activated protein kinase-independent pathway in B cells.

H L Li1, M S Forman, T Kurosaki, E Puré.   

Abstract

The tyrosine kinases Syk and Lyn are activated in B lymphocytes following antibody induced cross-linking of the B cell receptor for antigen (BCR). It has been suggested that activation of Syk is dependent on Lyn. We tested this hypothesis by comparing the phosphorylation and activation of several downstream effector molecules in parental DT40, DT40Syk- and DT40Lyn- B cells. The phosphorylation and activation of p90Rsk was ablated in Syk-deficient B cells but unaffected in Lyn-deficient B cells while the phosphorylation/activation of Ras GTPase activating protein (Ras GAP) and mitogen activated protein (MAP) kinase required both Syk and Lyn. Thus, these data indicate that Syk can be activated in the absence of Lyn after BCR cross-linking and results in the activation of p90Rsk via a MAP kinase-independent pathway in DT40Lyn- cells. We also demonstrated that BCR mediates the activation of p70S6k. However, activation of p70S6k in DT40Syk- and DT40Lyn- cells was comparable with that observed in parental cells. Thus, either Syk or Lyn may be sufficient for activation of p70S6k, or activation of p70S6k occurs independently of both Syk and Lyn. The kinase activity of Syk was required for the phosphorylation/activation of each of these downstream effector molecules but only the phosphorylation of Ras GAP was affected in cells expressing a mutant of Syk in which tyrosines 525 and 526 were substituted to phenlyalanines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218456     DOI: 10.1074/jbc.272.29.18200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Identification of protein tyrosine kinases required for B-cell- receptor-mediated activation of an Epstein-Barr Virus immediate-early gene promoter.

Authors:  Sandra Lavens; Emmanuel A Faust; Fang Lu; Michele Jacob; Messele Leta; Paul M Lieberman; Ellen Puré
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

2.  The tyrosine kinases Syk and Lyn exert opposing effects on the activation of protein kinase Akt/PKB in B lymphocytes.

Authors:  H L Li; W W Davis; E L Whiteman; M J Birnbaum; E Puré
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

3.  Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.

Authors:  James J Steinhardt; Raymond J Peroutka; Krystyna Mazan-Mamczarz; Qing Chen; Simone Houng; Carol Robles; Rolf N Barth; Joseph DuBose; Brandon Bruns; Ronald Tesoriero; Deborah Stein; Raymond Fang; Nader Hanna; Jason Pasley; Carlos Rodriguez; Mark D Kligman; Matthew Bradley; Joseph Rabin; Stacy Shackelford; Bojie Dai; Ari L Landon; Thomas Scalea; Ferenc Livak; Ronald B Gartenhaus
Journal:  Blood       Date:  2014-10-15       Impact factor: 22.113

Review 4.  Syk and pTyr'd: Signaling through the B cell antigen receptor.

Authors:  Robert L Geahlen
Journal:  Biochim Biophys Acta       Date:  2009-03-21

Review 5.  CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification.

Authors:  M Fujimoto; J C Poe; M Hasegawa; T F Tedder
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

6.  Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation.

Authors:  U D Bajpai; K Zhang; M Teutsch; R Sen; H H Wortis
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

7.  Novel Pathways Revealed in Bursa of Fabricius Transcriptome in Response to Extraintestinal Pathogenic Escherichia coli (ExPEC) Infection.

Authors:  Hongyan Sun; Peng Liu; Lisa K Nolan; Susan J Lamont
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

8.  In vitro and in vivo study of the expression of the Syk/Ras/c‑Fos pathway in chronic glomerulonephritis.

Authors:  Jiarong Gao; Liangbing Wei; Junmei Song; Hui Jiang; Yachen Gao; Xi Wu; Shuangzhi Xu
Journal:  Mol Med Rep       Date:  2018-08-03       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.